The Emergence of Lenacapavir as a Game-Changer in HIV Prevention

Lenacapavir, developed by Gilead Sciences, represents a significant advancement in human immunodeficiency virus (HIV) prevention and treatment. This long-acting injectable capsid inhibitor works by targeting the HIV capsid protein, disrupting multiple stages of the viral life cycle including entry, uncoating, and nuclear import. Unlike daily oral pre-exposure prophylaxis (PrEP) options like tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), lenacapavir is administered just twice a year subcutaneously, addressing adherence challenges that affect up to 80% of users in high-burden settings.

In South Africa, where approximately 7.8 million people live with HIV—representing nearly 20% of the global total—the drug's potential is immense. Landmark trials like PURPOSE 1, conducted across 54 sites in South Africa and Uganda, demonstrated 100% efficacy in preventing HIV acquisition among cisgender women over 52 weeks. This led to its approval by the South African Health Products Regulatory Authority (SAHPRA) in late 2025 and subsequent rollout plans for 2026.

However, as with any antiviral, the specter of resistance looms. A newly published study in Science Translational Medicine (January 2026 issue) has shed light on how HIV can develop resistance to lenacapavir through specific mutations, albeit at a substantial fitness cost to the virus. This research, building on global data but with direct relevance to South Africa's epidemic, underscores the need for vigilant monitoring in academic and clinical settings.

Details of the Groundbreaking Resistance Study

The study, titled "HIV can acquire mutations to resist lenacapavir at a fitness cost," was led by researchers examining in vitro and in vivo models of HIV-1 subtype C—the predominant strain in South Africa, accounting for over 95% of infections. Using serial passaging techniques, scientists exposed HIV cultures to increasing concentrations of lenacapavir, selecting for resistant variants over multiple generations.

Key mutations identified include Q67H and N74D in the capsid gene, which confer high-level resistance (up to 1,000-fold increase in IC50 values). These changes alter the capsid's binding pocket, preventing lenacapavir from locking the protein in its inhibited conformation. Step-by-step, the process unfolded as follows: initial low-level resistance emerged after 10-15 passages, escalating as dual mutations accumulated, mimicking real-world selective pressure.

Published on January 16, 2026, the findings were corroborated by patient-derived sequences from early lenacapavir users in treatment-experienced cohorts. While not exclusively South African-led, collaborators from the University of the Witwatersrand (Wits) Reproductive Health and HIV Institute (RHI) contributed subtype C isolates, linking the lab data to local epidemiology.

The Fitness Cost: Why Resistance May Not Spread Easily

A critical insight from the study is the "fitness cost" imposed by these mutations. Resistant viruses replicated 2-5 times slower than wild-type strains in the absence of drug pressure, due to impaired capsid stability and nuclear import efficiency. In competition assays, wild-type HIV outcompeted mutants within three passages without lenacapavir, suggesting natural barriers to transmission.

This mirrors patterns seen with other antiretrovirals, like M184V in reverse transcriptase, where resistance fades without ongoing drug exposure. For South Africa, this implies that while breakthrough infections could occur in non-adherent individuals, population-level resistance may remain low if rollout prioritizes high-risk groups like adolescent girls and young women (AGYW), who comprised 25% of new infections in 2024 per Thembisa model estimates.

Researchers modeled scenarios: in a cohort of 10,000 users, resistance prevalence stayed below 1% over five years, even with 20% imperfect adherence.

South Africa's Context: From Trial Success to Rollout Realities

South Africa's HIV response has evolved dramatically since the 2000s ART scale-up. With 5.7 million on treatment by 2025, PrEP uptake reached 1.2 million but stalled due to daily pill fatigue. Lenacapavir's PURPOSE 2 trial extension confirmed zero seroconversions in men and gender-diverse populations, prompting WHO's July 2025 recommendation for twice-yearly PrEP.

In October 2025, SANAC announced phased rollout starting in KwaZulu-Natal and Gauteng, targeting 500,000 doses by 2027 via public clinics. Professor Helen Rees of Wits RHI emphasized, "Lenacapavir could avert 200,000 new infections annually if scaled equitably." Yet, supply constraints limit initial access to under 3% of need, per Bhekisisa Centre for Health Journalism.

Academic institutions like Wits, University of Cape Town (UCT), and Stellenbosch University are pivotal, training healthcare workers and monitoring resistance through sentinel surveillance.

Stakeholder Perspectives: Optimism Tempered by Caution

Experts diverge on implications. Dr. Linda-Gail Bekker, Desmond Tutu HIV Centre at UCT, views it as a "chemical condom" for AGYW, stressing misinformation risks: "Trust in science is key amid vaccine hesitancy echoes." Gilead's Wendy Cupido affirmed local manufacturing talks to cut costs from $40/dose.

Conversely, treatment advocates like Treatment Action Campaign warn of over-reliance, citing dolutegravir resistance at 5-10% in failing patients. UNAIDS calls for combination strategies: lenacapavir plus behavioral interventions.

In higher education, Wits RHI's PhD programs in HIV virology are expanding, offering opportunities for researchers. Aspiring academics can explore research jobs or postdoc positions in this field to contribute to ongoing studies.

Implications for HIV Prevention Programs

• Adherence Boost: Six-month dosing could double PrEP persistence from 30% at six months.
• Resistance Monitoring: Need for genotypic testing in seroconverters, costing R500-1000 per sample.
• Equity Challenges: Rural access lags urban by 40%; mobile clinics proposed.
• Cost-Effectiveness: Models predict $1,200 saved per infection averted versus daily PrEP.

Globally, Eswatini and Zambia initiate rollouts in 2026, but South Africa's scale sets precedent. Integration with DREAMS 2.0 (Determined, Resilient, Empowered, AIDS-free, Mentored, Safe) targets 1.5 million AGYW.

Case Studies: Early Resistance Signals Worldwide

In a U.S. phase 3 trial, one seroconversion yielded Q67H, but the virus reverted post-treatment cessation. South Africa's first post-approval case, reported January 2026 in KwaZulu-Natal, showed transient N74D in a non-adherent user, resolving without transmission.

These underscore stepwise evolution: low-affinity mutations first, then high-level. Labs at Stellenbosch sequence 1,000 annual failures, finding baseline lenacapavir susceptibility intact.

For students in virology, such cases highlight evolutionary biology's role in drug design. Check career advice for academic CVs to enter this field.

Future Outlook: Next Steps in Research and Policy

PURPOSE 3 trials explore monotherapy limits, while Gilead advances oral lenacapavir. South Africa's 2026-2030 NSP targets 95-95-95 by integrating lenacapavir, with R18 billion budgeted.

Academic innovation accelerates: UCT's H3D lab develops next-gen capsid inhibitors. Challenges include pharmacovigilance for injection-site reactions (5-10%) and counterfeit risks.

Optimistically, modellers project 30% incidence drop by 2030 if resistance stays <2%.

Photo by Sincerely Media on Unsplash

Actionable Insights for Researchers and Policymakers

• Implement point-of-care genotyping in high-volume clinics.
• Train 10,000 nurses via university partnerships by 2027.
• Fund longitudinal cohorts tracking fitness reversion.
• Promote dual PrEP options to mitigate single-drug pressure.

Higher ed professionals can drive this: lecturer jobs in public health abound. Explore faculty positions to shape curricula on antiviral resistance.

In summary, while HIV mutation resistance to lenacapavir poses a challenge, its fitness cost offers reassurance. South Africa's academic ecosystem, from Wits to UCT, positions the nation to lead globally.

For career growth in HIV research, visit Rate My Professor, Higher Ed Jobs, and Higher Ed Career Advice.